Close

Roche licenses vemurafenib to Chugai

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider.

Related stories

Körber Launches PAS-X Neo MES for Small Pharma Manufacturers

Technology company Körber has introduced a new manufacturing execution...

How Bullying Affects Young People’s Mental Health

Bullying is sometimes brushed off as a normal part...

Supplement Distribution Is a cGMP Problem, Not Just a Logistics One

Three in four U.S. adults take dietary supplements, according...
- Advertisement -

F Hoffmann-La Roche has given marketing and development rights of BRAF inhibitor vemurafenib to Chugai Pharmaceutical. The licensing deal allows Roche to get milestone payments from Chugai Pharma.Chugai Pharma intends to begin a Phase I clinical trial for BRAF mutation-positive metastatic melanoma in Japan in 2012.Vemurafenib is being co-developed under a 2006 license and collaboration agreement between Roche and Plexxikon, a member of the Daiichi Sankyo Group.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Körber Launches PAS-X Neo MES for Small Pharma Manufacturers

Technology company Körber has introduced a new manufacturing execution...

How Bullying Affects Young People’s Mental Health

Bullying is sometimes brushed off as a normal part...

Supplement Distribution Is a cGMP Problem, Not Just a Logistics One

Three in four U.S. adults take dietary supplements, according...

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »